PhysioGenix’s Substantial Growth in 2010 Expected to Continue in 2011

Share Article

PhysioGenix experienced a tremendous year through the completion of a new research facility, addition of new capabilities and record high sales.

PhysioGenix, already a leader in customer focused contract research, expanded their research facilities, capabilities and research models in 2010. “We experienced tremendous growth in 2010 and anticipate additional growth in 2011,” stated PhysioGenix’s Director of Sales Darin Evans.

PhysioGenix was a winner of Companies to Watch for 2010 by the Wisconsin Entrepreneur Network (WEN) with support from the Wisconsin Department of Commerce and the Division of Entrepreneurship and Economic Development at the University of Wisconsin-Extension in association with the Edward Lowe Foundation to celebrate second-stage entrepreneurial companies. PhysioGenix proved that they deserved the award when they posted record high sales numbers while expanding the company during an economic recession.

One of the largest changes in 2010 was the completion of a new facility in December. The new facility has allowed PhysioGenix to streamline processes and cut costs, which the company is passing onto their clients. Furthermore, the new facilities enabled PhysioGenix to expand their capabilities and research models.

PhysioGenix is known for their excellence in diabetes and metabolic research. During the course of 2010, PhysioGenix expanded their capabilities to include cardiovascular studies. The company saw success over the course of the year and began to build a name for themselves in the field prompting further addition of new internal capabilities such as cardiovascular ultrasound imaging.

Last year also saw PhysioGenix continue their expansion of research models. Previously the company focused on rat studies. In 2010 PhysioGenix brought on a mouse expert and began selling mouse studies. PhysioGenix’s success with multiple mouse models has lead the company to dedicate an entire portion of their new lab facilities to mouse research.

PhysioGenix focuses on providing better customer service, coupled with accurate and reliable lab data that they present to their clients in near-real time. CEO Dr. Brian Curry explains, “Clients we work with come back for numerous studies because they state PhysioGenix provides a level of communication that is difficult to find with other preclinical CROs.”

Although 2010 was an enormous success for PhysioGenix, Dr. Curry is focused on the future, “We are positioned very well to take advantage of an improved economic environment in 2011 and this translates directly into more jobs, which is a good thing for all of us.”

To learn more about PhysioGenix go to


Share article on social media or email:

View article via:

Pdf Print

Contact Author

Darin Evans
Visit website